Summary slide.PNG (68.21 kB)

Encorafenib: A Review in Metastatic Colorectal Cancer with a BRAF V600E Mutation

Download (68.21 kB)
online resource
posted on 30.04.2021, 10:38 by Zaina T. Al-Salama

Declarations

Funding The preparation of this review was not supported by any external funding.

Authorship and Conflict of interest Zaina T. Al-Salama is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to the review and are responsible for the article content.

Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability Not applicable.


Additional information about this Adis Drug Review can be found here.



Abstract

Encorafenib (Braftovi®) is an oral small molecule BRAF inhibitor used in combination with cetuximab for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation, who have received prior systemic therapy. In a clinical trial in adults with BRAF V600E-mutated mCRC who had disease progression after one or two previous regimens (BEACON CRC), encorafenib plus cetuximab was associated with a significantly longer median overall survival (OS), a higher objective response rate (ORR) and longer median progression-free survival (PFS), compared with standard therapy. Encorafenib plus cetuximab had a manageable tolerability profile in BEACON CRC. Current evidence suggests that encorafenib plus cetuximab combination therapy is an important targeted regimen for patients with mCRC and a BRAF V600E mutation who have received prior therapy.


© Springer Nature Switzerland AG 2021



History

Exports